• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

辐射暴露、年轻以及女性性别与甲状腺乳头状癌中RET/PTC1和RET/PTC3的高患病率相关:一项荟萃分析。

Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: a meta-analysis.

作者信息

Su Xuan, Li Zhaoqu, He Caiyun, Chen Weichao, Fu Xiaoyan, Yang Ankui

机构信息

Department of Head and Neck, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

出版信息

Oncotarget. 2016 Mar 29;7(13):16716-30. doi: 10.18632/oncotarget.7574.

DOI:10.18632/oncotarget.7574
PMID:26918339
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4941346/
Abstract

BACKGROUND

RET/PTC rearrangements have been identified as a specific genetic event in papillary thyroid cancer (PTC). We conducted this meta-analysis to identify an enriched population who were more likely to occur RET/PTC fusion genes.

METHODS

All relevant studies in the PubMed, Web of Science, and Embase databases were searched up to June 2015. The studies found were screened according to our inclusion and exclusion criteria. All analyses were performed using STATA software.

RESULTS

Eventually, 38 eligible studies comprising 2395 participants were included. Overall analysis indicated that radiation exposure contributed to increased RET/PTC risk (OR = 2.82; 95%CI: 1.38-5.78, P = 0.005). Stratified analysis according to RET/PTC subtype and geographical area showed that this association was restricted to the RET/PTC3 subtype (OR = 8.30, 95%CI: 4.32-15.96, P < 0.001) in the Western population. In addition, age < 18 years, i.e., young age, was associated with higher prevalence of RET/PTC3 (OR = 2.03, 95%CI: 1.14-3.62, P = 0.017), especially in the radiation-exposure subpopulation (OR = 2.35, 95%CI: 1.01-5.49, P = 0.048). The association between female gender and RET/PTC1 risk was more significant in the PTC patients without radiation exposure (OR = 1.69, 95%CI: 1.04-2.74, P = 0.034).

CONCLUSION

Both radiation exposure and young age are associated with increased risk of RET/PTC3 and that female gender is associated with higher prevalence of RET/PTC1 in the subpopulation without radiation exposure. The RET/PTC status in combination with radiation exposure, age, and sex should be considered in the differential diagnosis of suspicious PTC.

摘要

背景

RET/PTC重排已被确定为甲状腺乳头状癌(PTC)中的一种特定基因事件。我们进行了这项荟萃分析,以确定更有可能出现RET/PTC融合基因的富集人群。

方法

检索了截至2015年6月在PubMed、科学网和Embase数据库中的所有相关研究。根据我们的纳入和排除标准对找到的研究进行筛选。所有分析均使用STATA软件进行。

结果

最终,纳入了38项符合条件的研究,共2395名参与者。总体分析表明,辐射暴露导致RET/PTC风险增加(OR = 2.82;95%CI:1.38 - 5.78,P = 0.005)。根据RET/PTC亚型和地理区域进行的分层分析表明,这种关联仅限于西方人群中的RET/PTC3亚型(OR = 8.30,95%CI:4.32 - 15.96,P < 0.001)。此外,年龄<18岁,即年轻,与RET/PTC3的较高患病率相关(OR = 2.03,95%CI:1.14 - 3.62,P = 0.017),尤其是在辐射暴露亚组中(OR = 2.35,95%CI:1.01 - 5.49,P = 0.048)。在无辐射暴露的PTC患者中,女性与RET/PTC1风险之间的关联更为显著(OR = 1.69,95%CI:1.04 - 2.74,P = 0.034)。

结论

辐射暴露和年轻均与RET/PTC3风险增加相关,而女性在无辐射暴露亚组中与RET/PTC1的较高患病率相关。在可疑PTC的鉴别诊断中应考虑RET/PTC状态与辐射暴露、年龄和性别的结合。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76db/4941346/a39513025b16/oncotarget-07-16716-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76db/4941346/a39513025b16/oncotarget-07-16716-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76db/4941346/a39513025b16/oncotarget-07-16716-g002.jpg

相似文献

1
Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: a meta-analysis.辐射暴露、年轻以及女性性别与甲状腺乳头状癌中RET/PTC1和RET/PTC3的高患病率相关:一项荟萃分析。
Oncotarget. 2016 Mar 29;7(13):16716-30. doi: 10.18632/oncotarget.7574.
2
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults.甲状腺结节中的RET/PTC重排:儿童和成人受照射与未受照射、恶性与良性甲状腺病变的研究
J Clin Endocrinol Metab. 2001 Jul;86(7):3211-6. doi: 10.1210/jcem.86.7.7678.
3
Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.甲状腺乳头状癌弥漫性硬化变异型:主要基因改变及预后意义
Histopathology. 2016 Jul;69(1):45-53. doi: 10.1111/his.12902. Epub 2016 Jan 11.
4
Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.台湾华人散发性乳头状甲状腺癌中RET重排(RET/PTC1、RET/PTC2、RET/PTC3和ELKS-RET)的低发生率
Thyroid. 2005 Apr;15(4):326-35. doi: 10.1089/thy.2005.15.326.
5
RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan).来自碘充足国家(日本)的甲状腺乳头状癌中的RET基因重排(RET/PTC1和RET/PTC3)
Cancer. 2005 Sep 1;104(5):943-51. doi: 10.1002/cncr.21270.
6
Influence of RET/PTC1 and RET/PTC3 oncoproteins in radiation-induced papillary thyroid carcinomas on amounts of cytoskeletal protein species.RET/PTC1 和 RET/PTC3 癌蛋白对放射性诱导的甲状腺乳头状癌细胞骨架蛋白种类数量的影响。
Amino Acids. 2011 Jul;41(2):415-25. doi: 10.1007/s00726-010-0733-x. Epub 2010 Sep 14.
7
[Dose-Response Dependences for Frequency of RET/PTC Gene Rearrangements in Papillary Thyroid Carcinoma after Irradiation. Simple Pooling Analysis of Molecular Epidemiological Data].[甲状腺乳头状癌放疗后RET/PTC基因重排频率的剂量反应依赖性。分子流行病学数据的简单合并分析]
Radiats Biol Radioecol. 2016 Jan-Feb;56(1):5-25.
8
RET/PTC rearrangement in thyroid tumors.甲状腺肿瘤中的RET/PTC重排
Endocr Pathol. 2002 Spring;13(1):3-16. doi: 10.1385/ep:13:1:03.
9
Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children.儿童辐射诱导性和散发性甲状腺乳头状癌形态学变异中ret原癌基因重排的独特模式。
Cancer Res. 1997 May 1;57(9):1690-4.
10
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma.RET/PTC3癌基因的强大促有丝分裂活性与其在甲状腺乳头状癌高细胞变体中的流行率相关。
Am J Pathol. 2002 Jan;160(1):247-54. doi: 10.1016/S0002-9440(10)64368-4.

引用本文的文献

1
Vitamin C in the Management of Thyroid Cancer: A Highway to New Treatment?维生素C在甲状腺癌治疗中的应用:通往新疗法之路?
Antioxidants (Basel). 2024 Oct 15;13(10):1242. doi: 10.3390/antiox13101242.
2
Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review.探索二肽基肽酶-IV(DPP-IV)和钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂在甲状腺乳头状癌中的临床应用:一项文献综述。
Front Pharmacol. 2024 Jan 16;15:1323083. doi: 10.3389/fphar.2024.1323083. eCollection 2024.
3
Exploring the clinical utility of angioinvasion markers in papillary thyroid cancer: a literature review.

本文引用的文献

1
The changing epidemiology of thyroid cancer: why is incidence increasing?甲状腺癌流行病学的变化:发病率为何上升?
Curr Opin Oncol. 2015 Jan;27(1):1-7. doi: 10.1097/CCO.0000000000000148.
2
Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters.钦奈人群中RET/PTC1和RET/PTC3基因重排的患病率及其与临床参数的相关性。
Tumour Biol. 2014 Oct;35(10):9539-48. doi: 10.1007/s13277-014-1909-x. Epub 2014 Jun 24.
3
Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
探讨脉管侵犯标志物在甲状腺乳头状癌中的临床应用价值:文献综述。
Front Endocrinol (Lausanne). 2023 Nov 27;14:1261860. doi: 10.3389/fendo.2023.1261860. eCollection 2023.
4
[Possibilities of the personalized approach to solitary thyroid nodules based on molecular profiling].基于分子谱分析的孤立性甲状腺结节个性化治疗方法的可能性
Chirurgie (Heidelb). 2024 Mar;95(3):179-185. doi: 10.1007/s00104-023-02002-9. Epub 2023 Dec 5.
5
Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer.RET抑制剂塞尔帕替尼在经过大量前期治疗的RET融合阳性乳头状甲状腺癌中实现持久疾病控制
Case Rep Oncol. 2022 Sep 27;15(3):833-840. doi: 10.1159/000526030. eCollection 2022 Sep-Dec.
6
RET kinase inhibitors for -altered thyroid cancers.用于RET基因改变的甲状腺癌的RET激酶抑制剂。
Ther Adv Med Oncol. 2022 Jun 21;14:17588359221101691. doi: 10.1177/17588359221101691. eCollection 2022.
7
Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects.塞普替尼治疗 RET 突变型甲状腺癌与胃肠道不良事件相关。
J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3824-e3829. doi: 10.1210/clinem/dgac337.
8
Significance of a PTEN Mutational Status-Associated Gene Signature in the Progression and Prognosis of Endometrial Carcinoma.PTEN 基因突变相关基因特征在子宫内膜癌进展和预后中的意义。
Oxid Med Cell Longev. 2022 Feb 23;2022:5130648. doi: 10.1155/2022/5130648. eCollection 2022.
9
The Combined Utility of HBME-1 and Galectin-3 Immunohistochemistry and BRAF V600E Mutations in the Diagnosis of Papillary Thyroid Carcinoma.HBME-1与半乳糖凝集素-3免疫组织化学及BRAF V600E突变在甲状腺乳头状癌诊断中的联合应用
Cureus. 2021 Dec 10;13(12):e20339. doi: 10.7759/cureus.20339. eCollection 2021 Dec.
10
Androgen Activity Is Associated With PD-L1 Downregulation in Thyroid Cancer.雄激素活性与甲状腺癌中PD-L1下调相关。
Front Cell Dev Biol. 2021 Aug 6;9:663130. doi: 10.3389/fcell.2021.663130. eCollection 2021.
甲状腺乳头状癌晚期伴发RAS、RET/PTC或BRAF基因突变。
Thyroid. 2014 Aug;24(8):1256-66. doi: 10.1089/thy.2013.0610. Epub 2014 Jun 10.
4
RET revisited: expanding the oncogenic portfolio.RET 再探:扩展致癌基因谱。
Nat Rev Cancer. 2014 Mar;14(3):173-86. doi: 10.1038/nrc3680.
5
Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.甲状腺乳头状癌中常同时出现 BRAF(V600E) 突变和 RET/PTC 重排。
Thyroid. 2014 Feb;24(2):254-9. doi: 10.1089/thy.2013.0235. Epub 2013 Aug 24.
6
Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.全球甲状腺癌发病率不断上升:流行病学与风险因素的最新情况
J Cancer Epidemiol. 2013;2013:965212. doi: 10.1155/2013/965212. Epub 2013 May 7.
7
Formation of carcinogenic chromosomal rearrangements in human thyroid cells after induction of double-strand DNA breaks by restriction endonucleases.限制酶诱导双链 DNA 断裂后人类甲状腺细胞中致癌染色体重排的形成。
Endocr Relat Cancer. 2012 May 3;19(3):271-81. doi: 10.1530/ERC-11-0314. Print 2012 Jun.
8
The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.转染/甲状腺乳头状癌酪氨酸激酶是一个雌激素依赖性基因,对于雌激素受体阳性乳腺癌细胞的生长是必需的。
Breast Cancer Res Treat. 2012 Jun;133(2):487-500. doi: 10.1007/s10549-011-1775-9. Epub 2011 Sep 24.
9
Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.塞尔维亚甲状腺乳头癌的突变与临床病理分析。
Endocr J. 2011;58(5):381-93. doi: 10.1507/endocrj.k11e-054. Epub 2011 Apr 15.
10
Chromosomal rearrangements in post-Chernobyl papillary thyroid carcinomas: evaluation by spectral karyotyping and automated interphase FISH.切尔诺贝利事故后乳头状甲状腺癌中的染色体重排:通过光谱核型分析和自动间期荧光原位杂交进行评估
J Biomed Biotechnol. 2011;2011:693691. doi: 10.1155/2011/693691. Epub 2011 Mar 13.